Hemab Therapeutics (NASDAQ:COAG) has launched a pivotal Phase 3 trial of its experimental bleeding-disorder treatment sutacimig, moving its lead program into late-stage development as it prepares additional data presentations in December and February. On the company’s third-quarter earnings call, Chief Executive Officer Benny Sørensen said the SOLARA study will test weekly sutacimig injections in people […]

Trevi Therapeutics (NASDAQ:TRVI) said it remains on track to report results from its lead chronic cough trials in 2027 and 2028, while preparing a new study in patients with interstitial lung disease other than idiopathic pulmonary fibrosis. On its third-quarter 2026 earnings call, the company also outlined an upcoming assessment that could increase enrollment in […]

Lexicon Pharmaceuticals (NASDAQ:LXRX) expects two key milestones in the first quarter of 2027: results from a pivotal heart disease trial and a resubmission of its application for a type 1 diabetes treatment, executives said on the company’s third-quarter earnings call. The company reported a third-quarter net loss of $14.0 million, compared with $12.8 million a […]

Ultragenyx Pharmaceutical (NASDAQ:RARE) said its third quarter included two U.S. gene therapy approvals, a failed late-stage Angelman syndrome study, the termination of its Wilson disease program and restructuring actions intended to support GAAP profitability in 2027. Chief Executive Officer and President Emil Kakkis said the Food and Drug Administration approved GENGLYCOS for glycogen storage disease […]

Recursion Pharmaceuticals (NASDAQ:RXRX) reported updated clinical data for its investigational treatment for familial adenomatous polyposis, or FAP, along with early activity in its solid-tumor program REC-1245, partnership progress and an extension of its expected cash runway into 2029. The company also announced that its board unanimously appointed Fred Hassan as non-executive chair. Hassan previously served […]